Adolescents

Data from the DPV cohort show a reduced risk for severe hypoglycemia and diabetic ketoacidosis among children and young people with type 1 diabetes using continuous glucose monitoring rather than self-monitored blood glucose.

Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

“Almost no one” who is islet autoantibody negative at age 10 years despite a high familial risk for type 1 diabetes will develop clinical diabetes by the age of 18, report researchers.

The incidence and burden of type 2 diabetes in young people aged 15–39 years are increasing worldwide, show data from the Global Burden of Disease Study.

Real-world use of hybrid closed-loop insulin delivery is associated with improved glycemic control and sleep quality, as well as reduced fear of hypoglycemia in children and young people with type 1 diabetes, shows a UK study.

Click through to read more on this announcement

Click through to read more on this announcement

Nearly half of all cases of type 1 diabetes occurring annually in children and adolescents may go undiagnosed, especially in low- and middle-income countries, show the results of a modeling study.